IRONWOOD PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Description as filed by funds: Election of Directors. To elect nine director nominees numbered 01 through 09 to serve for a one-year term extending until the 2026 annual meeting of stockholders and their successors are duly elected and qualified: Alexander Denner, Ph.D.

IRONWOOD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Alexander Denner, Ph.D.”): 108,426,760 for, 5,238,211 withheld, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders elected nine director nominees, each to serve on the board of directors of the Company for a one-year term extending until the 2026 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her death, resignation or removal, based …”
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 36,147,981 for, 20,063 withheld.

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

Description as filed by funds: Election of Directors. To elect nine director nominees numbered 01 through 09 to serve for a one-year term extending until the 2026 annual meeting of stockholders and their successors are duly elected and qualified: Andrew Dreyfus

IRONWOOD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Andrew Dreyfus”): 110,282,918 for, 3,382,053 withheld, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders elected nine director nominees, each to serve on the board of directors of the Company for a one-year term extending until the 2026 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her death, resignation or removal, based …”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 35,839,176 for, 6,863 withheld, 322,005 abstained.

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

Description as filed by funds: Election of Directors. To elect nine director nominees numbered 01 through 09 to serve for a one-year term extending until the 2026 annual meeting of stockholders and their successors are duly elected and qualified: Catherine Moukheibir

IRONWOOD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Catherine Moukheibir”): 110,936,589 for, 2,728,382 withheld, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders elected nine director nominees, each to serve on the board of directors of the Company for a one-year term extending until the 2026 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her death, resignation or removal, based …”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 36,017,194 for, 150,850 withheld.

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

Description as filed by funds: Election of Directors. To elect nine director nominees numbered 01 through 09 to serve for a one-year term extending until the 2026 annual meeting of stockholders and their successors are duly elected and qualified: Jay Shepard

IRONWOOD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jay Shepard”): 111,094,136 for, 2,570,835 withheld, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders elected nine director nominees, each to serve on the board of directors of the Company for a one-year term extending until the 2026 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her death, resignation or removal, based …”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 36,161,754 for, 6,290 withheld.

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

Description as filed by funds: Election of Directors. To elect nine director nominees numbered 01 through 09 to serve for a one-year term extending until the 2026 annual meeting of stockholders and their successors are duly elected and qualified: Jon Duane

IRONWOOD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jon Duane”): 109,604,574 for, 4,060,397 withheld, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders elected nine director nominees, each to serve on the board of directors of the Company for a one-year term extending until the 2026 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her death, resignation or removal, based …”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 35,825,403 for, 20,636 withheld, 322,005 abstained.

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

Description as filed by funds: Election of Directors. To elect nine director nominees numbered 01 through 09 to serve for a one-year term extending until the 2026 annual meeting of stockholders and their successors are duly elected and qualified: Julie McHugh

IRONWOOD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Julie McHugh”): 109,518,572 for, 4,146,399 withheld, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders elected nine director nominees, each to serve on the board of directors of the Company for a one-year term extending until the 2026 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her death, resignation or removal, based …”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 36,147,964 for, 20,080 withheld.

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

Description as filed by funds: Election of Directors. To elect nine director nominees numbered 01 through 09 to serve for a one-year term extending until the 2026 annual meeting of stockholders and their successors are duly elected and qualified: Mark Currie, Ph.D.

IRONWOOD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Mark Currie, Ph.D.”): 110,739,267 for, 2,925,704 withheld, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders elected nine director nominees, each to serve on the board of directors of the Company for a one-year term extending until the 2026 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her death, resignation or removal, based …”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 35,839,176 for, 6,863 withheld, 322,005 abstained.

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

Description as filed by funds: Election of Directors. To elect nine director nominees numbered 01 through 09 to serve for a one-year term extending until the 2026 annual meeting of stockholders and their successors are duly elected and qualified: Marla Kessler

IRONWOOD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Marla Kessler”): 110,720,078 for, 2,944,893 withheld, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders elected nine director nominees, each to serve on the board of directors of the Company for a one-year term extending until the 2026 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her death, resignation or removal, based …”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 35,839,176 for, 6,863 withheld, 322,005 abstained.

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

Description as filed by funds: Election of Directors. To elect nine director nominees numbered 01 through 09 to serve for a one-year term extending until the 2026 annual meeting of stockholders and their successors are duly elected and qualified: Thomas McCourt

IRONWOOD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Thomas McCourt”): 110,995,716 for, 2,669,255 withheld, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders elected nine director nominees, each to serve on the board of directors of the Company for a one-year term extending until the 2026 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her death, resignation or removal, based …”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 36,161,754 for, 6,290 withheld.

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

Description as filed by funds: APPROVAL, BY NON-BINDING ADVISORY VOTE, OF THE COMPENSATION PAID TO THE NAMED EXECUTIVE OFFICERS.

IRONWOOD PHARMACEUTICALS INC.’s own tally for this item (“2. On a non-binding advisory basis, the compensation paid to the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting, based on the following votes”): 110,089,576 for, 3,511,070 against — passed, per its Form 8-K filed June 12, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders approved, on a non-binding advisory basis, the compensation paid to the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting, based on the following votes:”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 59 managers: 35,839,176 for, 328,868 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 141 managers: 77,221,063 for, 730,677 against, 5,650,928 withheld, 1,522 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: RATIFICATION OF THE SELECTION OF ERNST & YOUNG LLP AS IRONWOOD PHARMACEUTICALS, INC.'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR 2025.

IRONWOOD PHARMACEUTICALS INC.’s own tally for this item (“3. The selection of Ernst & Young LLP as the Company's independent registered public accounting firm for 2025, based on the following votes”): 128,241,210 for, 2,621,956 against — passed, per its Form 8-K filed June 12, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for 2025, based on the following votes:”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 36,168,027 for, 17 against.

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.